Jul 20, 2023 7:03am EDT Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
Jul 18, 2023 7:03am EDT Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
Jun 29, 2023 5:04pm EDT Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
Jun 16, 2023 7:38am EDT Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
May 16, 2023 8:29am EDT Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
Apr 24, 2023 7:00am EDT Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
Mar 31, 2023 7:00am EDT Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
Mar 06, 2023 7:00am EST Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
Feb 27, 2023 7:00am EST Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
Feb 02, 2023 8:30am EST Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
